Urinary intestinal alkaline phosphatase (EC 3.1.3.1; lAP) is a marker of the 83 segment of the human kidney proximal tubule. An accurate enzyme-antigen Immunoassay (EAIA) with a high-affinity specific monoclonal antibody (IAP25O) developed for this marker has a detection limit below the lowest lAP activity found in urine samples of normal subjects. The intra-and interassay CVs were <5%. Mean analytical recovery of pure lAP added to urine was 102% (SD 6%), and the EAIA results correlated well with immunoreactivity (measured by a sandwich ELISA), suggesting that the EAIAdetected all of the lAP in urine. In healthy individuals (ages 20-80 years) the lAP concentrations, expressed as urinary creatinine ratios, ranged from 0.1 to 2.0 U/g (5-95 percentiles) without major differences related to sex and age. Workers exposed to mercury, which affects the 83 segment, showed an increased lAP elimination; abusers of analgesics, which affect more distal parts of the nephron, did not. As opposed to currently measured markers, the EAIA offers easy, accurate, and precise measurementof early alterations in the S3 segment. For many years an active search has been under way for proteins or other molecules for which appearance or concentration change in urine indicates alterations of cell integrity, in particular of nephron segments. Differences in the distribution of these markers along the nephron are considered to be useful in identifying the specific anatomical site of nephrotoxin-induced damage. Indeed, drugs and other chemical substances, e.g., analgesics (1), mercury (2), cisplatin (2), aminoglycosides (3), and cyclosporine (4), exert their toxic effects at different positions along the nephron.
the presence of inhibitors and activators. This is particularly well documented for -microglobulin, necessitating oral bicarbonate loading some hours before its determination in the urine to prevent acid-dependent -microglobulin degradation in the urine (6). Finally, almost no studies have correlated abnormal enzymuria with verified functional or histological evidence of tubular damage (7) .
The use of monoclonal antibodies directed against particular antigens localized along the nephron can lead to the identification of unique renal markers that are specific for different anatomical sites in the nephron and that can be detected reproducibly by immunoaasay 
techniques (8). Using a monoclonal antibody
(1AP250) to human intestinal alkaline phosphatase (TAP), we demonstrated (9) that, in the normal human kidney, LAP is exclusively located at the brush border of tubuloepitheHal cells present in the S3 segment of the proximal tubules, from which it can be released into urine.6 Here we describe an accurate and precise assay of this marker.
Materials and Methods
Reagents and Apparatus p-Nitrophenyl phosphate was purchased from Janesen Chiinica (Beerse, Belgium). Trypsin (type ifi; 11.250 kU/g), poly-L-lysine, To establish normal reference values, we investigated the distribution of urinary LAP activities in relation to age and sex for subjects recruited from two large-scale epidemiological studies. The first group was taken from a project on early indicators of nephrotoxicity in workers due to environmental pollutants (1989-1990; 72 women and 311 men). The second consisted of 37 men and 89 women, selected from control subjects for a longitudinal prospective study on the role of analgesics abuse in the development of chronic renal failure (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) . To complete the range of ages in both sexes, we collected urine samples from women younger than 30 years (n = 17) and in men older than 60 years (n = 16).
Two toxin-exposed groups were analyzed. Analgesics abusers (n = 160) were studied as a nonrisk group, because this group is primarily affected in the renal medulla. On the other hand, mercury-exposed workers (n = 104) were chosen as a risk group manifesting changes of the 53 segment, because mercury particularly affects this segment. The analgesics abusers were selected from the general population along with their age-and sex-matched controls (n = 160). Mercuryexposed workers were recruited in three chioroalkali factories, including greatly exposed workers from Bansk#{225} Bystrica (Czechoslovakia), and their controls (n = 83) in other factories. On the basis of questionnaire data, potential control subjects exposed to nephrotoxic products (i.e., lead, cadmium, mercury, and organic solvents) were excluded.
Subjects with hypertension (blood pressure >160/100 mmHg, with or without antihypertensive treatment) and those with a positive Combur#{174} dipstick test for glucose were excluded.
Thirty-five patients (20 women and 15 men, ages 18-75 years) with various degrees of proteinuria (300-5000 mg/L) were followed in the outpatient Nephrology Clinic (University Hospital Antwerp, Belgium). LAP in serum was determined from total AP activity and from the isoenzyme pattern obtained by agarose-gel electrophoresis (11). Urinary LAP was measured as described above. we stored them at 4#{176}C in a container with silica gel as the desiccant.
To each well of a microtiter plate strip, we added 100 iL of assay diluent (PBS containing, per liter, 1 g of Human dimeric fetal lAP (140 kDa) was purified from meconium as described elsewhere (9) . The preparation had a specific activity of 2900 kU/g and a final purity of >95%, as evidenced by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (12), and was stored in liquid nitrogen as a stock solution (300 UIL) in 20-pL aliquots in assay diluent. From this solution, standards ranging from 0.10 to 10.00 U/L were prepared by serial dilution in the assay diluent before each assay.
One unit of activity (1 U) was defined as the amount of enzyme (9, 15) . Briefly, we cut 1.5-mmthick slices of renal tissue from the surface of the kidney to the papilla, fixed them for 1.5 h in buffered 40 milL formaldehyde, and embedded them in low-melting-point paraflln (16). We mounted 4-tim-thick sections on poly-L-lysine-coated slides and treated them with trypsin.
7To convert to U/mol, divide by 0.00884. Binding of the monoclonal antibody 1AP250 was revealed by an indirect avidin-biotin--peroxidase method with use of 3-amino-9-ethyl carbazole and H202 as substrates.
The sections were counterstained with methyl green and mounted in glycerine gelatin.
Results

Assay Validation
Increasing amounts of stabilizing buffer added to urine progressively enhanced the recovery of urinary LAP by 20% (SD 4%; n = 10) during subsequent EAIA measurements, reaching a plateau with the addition of 50 pL of buffer per 1 mL of urine. The presence of stabilizing buffer had no influence on urinary creatinine determinations.
The pH of stabilized urine samples varied between 6.0 and 7.5. The LAP activity in sediments encountered in -10% of stabilized urine samples was below the detection limit after Triton X-100 extraction. Therefore, enzyme assays could be performed on urine supernates.
Analysis of the fractional binding of the LAP in standards and in urine samples as a function of time confirmed that equilibrium in the EAJA was reached more rapidly at 37#{176}C than at room temperature ( Figure  1 ). At 37#{176}C, equilibrium was reached after 6 h (3 t112, equivalent to 87.5% of the amount bound at equilibrium) as opposed to after -10 h at room temperature. The long equilibration times necessitated including an overnight incubation step in the protocol, which resulted in complete binding of LAP in the standard and in the urine samples (n = 20).
Urinary LAP, having a smaller mass (83 kDa) than the LAP in the standard (140 kDa) (9), reached equilibrium slightly faster (Figure 1 for three weeks at 4 or -80 #{176}C (Figure 2 ). For storage times up to six months, 4#{176}C was preferred over -20 #{176}C. A part of the activity loss during storage at -20 #{176}C could be explained by the effect of a freezing-thawing cycle. We experimentally verified this in seven stabilized urine samples frozen at -20 #{176}C and thawed immediately; mean activity decrease was 8% (SD 9%). Small variations in pH in stabilized urine samples (pH 6.0-7.5) had no influence on the stability of urinary LAP activities.
To investigate potential interferences from osmolality in urine, various NaCl or urea concentrations (0-500 mmol/L) were added to four different urine samples. LAP activity was not significantly modified by these additives. 
Values of Urinary lAP
Although no major differences were noticed between the distribution of the urinary LAP activity/creatinine ratios in women and men according to age (Figure 4) , cutoff values (P95) for women were slightly greater. Ln both groups the median (P50) remained stable over the different age categories. In only 2 of these 12 subjects was LAP increased in serum. hi 7 of the 35 proteinuric patients, LAP in serum was >10 UIL (95th percentile; 18), and LAP in urine was increased in only 2 of the 7.
Localization of lAP in Normal Human Kidney
Positive immunohistochemical staining for LAP was present only on the brush border of proximal tubule cells in the outer stripe of the outer medulla and in the medullary rays ( Figure 6A ). According to the topological distribution of these LAP-containing tubular crosssections in the kidney (medullary rays and outer stripe of outer medulla), and in view of the well-developed brush border in these cells, we concluded that LAP was present exclusively in the S3 segment of the proximal tubule, according to the criteria of the International Society of Nephrology (19) (Figure 6B ). Figure   7 demonstrates that LAP activities were greater in mercury-exposed workers (n = 104) than in the controls (n = 83; Mann-Whitney U test: P <0.001). Mercury exposure was measured in urine, and median (range) values were 89.3 nmol/g (25.4-895.7 nmo]Ig) and 6.5 nmol/g (1.0-23.5 nmol/g) for exposed workers and control subjects, respectively. LAP activities in an- easy and precise assay system, and stability. Here we show that LAP has these prerequisites for being an ideal marker.
Epidemiological Data
The human kidney contains two antigenically distinct #{192}Y isoenzymes, tissue-nonspecific AP and LAP (20) , both contributing to #{192}Y activity in urine (20) (21) (22) . LAP is exclusively in the brush border of the S3 cells of the proximal tubule, whereas tissue-nonspecific AP is bcated throughout the entire proTiniRl tubule (9) . This contrasts with many other urinary markers (e.g., N-acetylglucosaminidase, which is found throughout the proximal tubule as well as in renal papillae and glomeruli; 23).
Despite its lower molecular mass (85 kDa) (9), urinary LAP retains almost all its biochemical and immunological characteristics; its origin is most likely renal. The extracellular luminal-site localization of the ectoenzyme LAP in the S3 cells makes its release into the tubular fluid obvious. LAP in serum, with its 140-kDa molecular mass, cannot be filtered through the glomeruli of the normal kidney (24) . Our findings in proteinuric patients also suggest that urinary LAP does not originate from serum. Total AP has often been analyzed in urine (25), but the measurement of its activity is complicated by interfering material (26). #{192}Y activity can only be determined after inhibitors (e.g., pyrophosphates) are removed by dialysis. Drugs and drug metabolites (e.g., nitrofuran- 26) also interfere with AP determination. In our EAIA, the immunological recognition of LAP is not hampered by the urinary matrix in urine samples diluted twofold, nor is LAP activity measurement affected by inhibitors or activators.
The distribution of LAP activities in urine samples from normal subjects shows the assay to be sufficiently sensitive to accurately quantify LAP, and the analytical recoveries are complete. Because urinary LAP concentrations are extremely low, i.e., in nanomoles per liter, overnight incubation is necessary for complete equilibrium to be reached.
Both the enzyme activity and the irnmunoreactivity of urinary LAP are stable in buffered urine samples (pH >6.0) stored at 4#{176}C for at least three weeks. Optimal long-term preservation is at -80 #{176}C. This contrasts with the stability of $-microglobulin, which can be degraded even before voiding (6) because of the acidity in the urinary bladder. Buffering of freshly voided urine is adequate for LAP measurement.
Recent results in workers exposed to mercury, a well-known tubular toxin interfering preferentially with the 53 segment of the proximal tubule, showed that LAP was increased in these workers compared with control subjects (27) . hi contrast, analgesics abusers did not show increased LAP activities compared with ageand sex-matched control subjects, which agrees with the fact that analgesics primarily involve the renal papillae (28 their controls are somewhat higher than those for the mercury-exposed workers because the former aremostly older women and the latter are mostly younger men.
In conclusion, by using a high-affinity monoclonal antibody (9) with a high specificity for active LAP (specific activity of 3 MU/C, 12), we developed a simple, reproducible, and highly sensitive EAIA. LAP in urine is a promisingmarker of alterations in the 53 segment of the human proximal tubule.
